Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CEST

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08/19 PFIZER : U.S. pharmaceutical firms to extend investments in Egypt
08/18 GLAXOSMITHKLINE : taps Baltimores Insilico for AI-based drug discovery
08/17 RECENT FINDINGS FROM GLAXOSMITHKLINE : 01 biomarker for...
08/17 NEW CYTOKINES FINDINGS FROM GLAXOSMI : A Reversible and Selective Antagonist of ..
08/17 RESEARCH FROM GLAXOSMITHKLINE PLC YI : lamotrigine and fatal...
08/17 GLAXOSMITHKLINE : New Data from GlaxoSmithKline plc Illuminate Findings in Vacci..
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/15 GLAXOSMITHKLINE PLC. (ADR)(NYSE : GSK) Restructuring Takes A Toll on Ionis Pharm..
08/14 Featured Company News – GlaxoSmithKline Drops Options to Licence Inoter..
08/11 GLAXOSMITHKLINE PLC (ADR) (NYSE : GSK) And Rolls Royce To Expect UK Fraud Office..
More news
News from SeekingAlpha
08/21 CytoDyn advancing (slowly) late-stage study of PRO 140 in HIV patients; FDA m..
08/18 SNIPPET ROUNDUP : Transparency For Straumann But A Black Box For Pfizer
08/17 'Safer' Dividend Follower Favorites And Rogues Led By RAIT Financial & Chico,..
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
08/15 BRISTOL-MYERS SQUIBB : HIV Franchise Was Never A Big Part Of The Game Plan
Financials ( GBP)
Sales 2017 30 168 M
EBIT 2017 8 507 M
Net income 2017 4 165 M
Debt 2017 14 104 M
Yield 2017 5,41%
P/E ratio 2017 19,30
P/E ratio 2018 15,67
EV / Sales 2017 2,88x
EV / Sales 2018 2,78x
Capitalization 72 769 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,5  GBP
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-5.28%93 742
JOHNSON & JOHNSON15.83%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.86%194 554
MERCK AND COMPANY5.27%167 705